13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001388551
Total reported value
$1.9M
$1.9M
7 檔
212.3%
At the close of Q1 2026, Caxton CORP disclosed equity holdings valued at approximately $1.9M, spread across 7 reported holdings.
In Q1 2026, Caxton CORP adopted a defensive or profit-taking posture, trimming 0 positions and completely liquidating 5 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including GLD, BRK-B, KYTX) accounted for 212.3% of total reported equity market value during Q1 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GLD | Spdr Gold Shares | ETF-Commodities | 81.50% | -81.50% | EXIT | |
| 2 | BRK-B | Berkshire Hathaway Inc-cl B | Stock-Other | 8.66% | +11.69% | +2.39% | |
| 3 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 4.03% | +1.91% | — | |
| 4 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 1.99% | +2.27% | — | |
| 5 | XFOR | X4 Pharmaceuticals Inc | Stock-Other | 1.60% | +2.32% | — | |
| 6 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 1.19% | +1.93% | — | |
| 7 | ALXO | Alx Oncology Holdings Inc | Stock-Other | 1.04% | +1.30% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | GLD | Spdr Gold Shares | +17% | +9.46% | Add |
| 2 | BRK-B | Berkshire Hathaway Inc-cl B | +0.3% | +2.39% | Add |
| 3 | XFOR | X4 Pharmaceuticals Inc | +0.2% | — | Unchanged |
| 4 | KYTX | Kyverna Therapeutics Inc | -0.1% | — | Unchanged |
| 5 | IKT | Inhibikase Therapeutics Inc | -0.2% | — | Unchanged |
| 6 | LXEO | Lexeo Therapeutics Inc | -1.3% | — | Unchanged |
| 7 | SYRE | Spyre Therapeutics Inc | — | EXIT | Sold out |
| 8 | BRD1EUR | Mind Medicine Mindmed Inc | — | EXIT | Sold out |
| 9 | CMPX | Compass Therapeutics Inc | — | EXIT | Sold out |
| 10 | ALXO | Alx Oncology Holdings Inc | — | NEW | New buy |
| 11 | SABS | Sab Biotherapeutics Inc | — | EXIT | Sold out |
| 12 | CNTX | Context Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Caxton CORP reported a total U.S. public equity portfolio value of $1.9M across 7 disclosed positions in Q1 2026.
During Q1 2026, Caxton CORP's top holdings by market value included GLD (81.5%)、BRK-B (8.7%)、KYTX (4.0%). The largest single position, GLD, represented 81.5% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
ALXO
市值: $42.0K
Top Position Liquidated / Trimmed
SYRE
前期市值: $292.2K
In Q1 2026, Caxton CORP made 8 total portfolio adjustments, initiating 1 new buys, adding to 2 positions, trimming 0 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.